Can We Define High-risk DAPT Patients in USA Practice? - ppt download
Two further studies support three-month DAPT following PCI
Bleeding and Ischemic Risk Prediction in Patients With High Bleeding Risk (an EVOLVE Short DAPT Analysis) - ScienceDirect
Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review | Published in Journal of Brown Hospital Medicine
Two further studies support three-month DAPT following PCI
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation - ScienceDirect
Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science | tctmd.com
BostonSci Cardiology on X: "See how SYNERGY™ BP Stent performed 12-months post-DAPT discontinuation in the EVOLVE Short #DAPT Trial: https://t.co/fQIpaJOGOC Safety Info: https://t.co/aA0ofN4r9t https://t.co/lrWq5mVKBT" / X
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
Studying DAPT – SYNERGY Stent - Boston Scientific
Session evaluation and key learnings
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Antiplatelet therapy after percutaneous coronary intervention - EuroIntervention
XIENCE Stent: Protecting Patients with Short DAPT Needs | Abbott
Davide Capodanno on X: "My editorial to the EVOLVE Short DAPT study, from @ajaykirtane and colleagues (congratulations!). Interesting result and insightful data in a rapidly changing scenario that has more to say.
